exenatide — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

exenatide appears in hypotheses across 5 disease domains: ALS, Epilepsy, Inflammatory bowel disease, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: AMPK.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for exenatide

ALS 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	amyotrophic lateral sclerosis	0.208	Mid	partial evidence	none

Epilepsy 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	spike-wave seizures	0.208	Mid	novel signal	none
AMPK	epileptiform network activity	0.208	Mid	novel signal	none

Inflammatory bowel disease 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	intestinal epithelial repair	0.208	Mid	novel signal	none
AMPK	intestinal inflammation	0.208	Mid	novel signal	none

Pancreatic cancer 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
SIRT1	proliferation	0.220	Mid	reproduces known	none
AMPK	pancreatic ductal adenocarcinoma	0.208	Mid	novel signal	none
AMPK	pancreatic cancer progression	0.208	Mid	novel signal	none
AMPK	invasion	0.208	Mid	novel signal	none

Rheumatoid arthritis 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
MMP-3	rheumatoid arthritis	0.208	Mid	partial evidence	none

← All drugs